NIH Official Discusses Need To Issue Exclusive License To Drug Company For Zika Vaccine Development With U.S. House, Senate Staff

CQ HealthBeat: NIH Tries to Ease Concerns About Zika Vaccine Deal
“The federal government is considering granting a pharmaceutical company an exclusive license to further develop a taxpayer-funded vaccine for the Zika virus, just weeks after a similar arrangement was scuttled following blowback from health groups and lawmakers. … In a pair of conference calls with House and Senate staff members, [NIAID Director Anthony] Fauci made a case for why the government needs industry partners to get a Zika vaccine to market…” (Siddons, 10/16).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.